Successful treatment of refractory anti-signal recognition particle myopathy using abatacept

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 379-380

  Maeshima, Keisuke ^a   Kiyonaga, Yasuhiro ^a   Imada, Chiharu ^a   Iwakura, Mikako ^a   Hamasaki, Hajime ^a   Haranaka, Miwa ^a   Ishii, Koji ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; CREATINE; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; JO 1 ANTIBODY; METHOTREXATE; MIZORIBINE; PREDNISONE; SIGNAL RECOGNITION PARTICLE; TACROLIMUS; TOCILIZUMAB;

ADULT; ANTI SIGNAL RECOGNITION PARTICLE MYOPATHY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LIMB WEAKNESS; MALE; MIDDLE AGED; MUSCLE BIOPSY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, ANTI-IDIOTYPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCULAR DISEASES; SIGNAL RECOGNITION PARTICLE; TREATMENT OUTCOME;

EID: 84892523127     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket251     Document Type: Letter

References (10)

1. Miller T, Al-Lozi MT, Lopate G et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-8.
2. Kao AH, Lacomis D, Lucas M et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209-15.
3. Hengstman GJ, ter Laak HJ, Vree Egberts WT et al. Antisignal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-8.
4. Arlet JB, Dimitri D, Pagnoux C et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16: 334-6.
5. Valiyil R, Casciola-Rosen L, Hong G et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010;62:1328-34.
6. Platt AM, Gibson VB, Patakas A et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010;185:1558-67.
7. Lumsden JM, Roberts JM, Harris NL et al. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection. J Immunol 2000;164:79-85.
8. Buch MH, Boyle DL, Rosengren S et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
9. Izawa A, Sayegh MH, Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Transplant Proc 2004;36(2 Suppl):570S-573S.
10. Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011;78:431-2.